360° SearchNetwork Hot Spots Trends Time Series

Vytorin

Type: Product

Name: Vytorin

First reported May 20 2013 - Updated May 20 2013 - 1 reports

ASTRAZENECA - Tremendous Pressure - Messiah to be Found - new market research report

AZN reported its 4Q-2102 financial results, revenue declined by 15% while core EPS was up by 1% driven by one time tax benefits and lower operating costs. For 2013, the company has guided mid to high single digit decline in revenue, while core EPS should ... [Published TransWorldNews - May 20 2013]

Entities: Vytorin, AstraZeneca PLC, Brilinta, Crestor

First reported May 19 2013 - Updated May 20 2013 - 1 reports

Statin Users May Have a Reason to Rejoice After This Data

Filed under: Investing Whether or not you've been keeping tabs, the American Society of Clinical Oncology's annual meeting is less than two weeks away. ASCO, as it's more commonly known, is arguably the single-most important event in the biotechnology ... [Published EquityJungle - v0.1 - May 19 2013]

Entities: Statins, LDL-cholesterol, Statin, Cholesterol

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Top 10 Cardio Drugs 2012

For years, cardio was king. The world's all-time best-selling drug, Pfizer's ($PFE) Lipitor, after all, is an antihyperlipidemic drug. Cardio drugs have traditionally made up one of the largest categories of therapeutic treatment in the drug universe ... [Published FiercePharma - May 16 2013]

Entities: Drugs, EvaluatePharma Ltd, Antihypertensive Drug, Lipitor

First reported May 09 2013 - Updated May 10 2013 - 3 reports

The FDA Approval Of Merck's Cholesterol Lowerer, Liptruzet, Doesn't Help Its Credibility

Josh Bloom recently wrote a very provocative piece entitled: "How can Merck look itself in the mirror?" Bloom is concerned that this once greatly admired pharmaceutical company has lost its way by bringing to market the LDL cholesterol lowering drug, ... [Published Forbes.com - May 10 2013]

Entities: Cholesterol, Zetia, Drugs, Statins, Vytorin

First reported May 07 2013 - Updated May 08 2013 - 3 reports

Merck & Co Inc

Merck's Liptruzet Approved in the US - Analyst Blog

Merck ( MRK ) recently gained US Food and Drug Administration (FDA) approval for its combination cholesterol treatment, Liptruzet. The FDA granted approval to Liptruzet for the treatment of elevated low-density lipoprotein (LDL) cholesterol in patients ... [Published Nasdaq - May 07 2013]

Entities: Zetia, Vytorin, Merck & Co Inc, Lipitor

First reported May 06 2013 - Updated May 07 2013 - 3 reports

Lipitor

Merck's Liptruzet may mend IMPROVE-IT, but offers little in the short run

The approval of Merck's new cholesterol lowering combo drug Liptruzet (Zetia-plus-atorvastatin) has been met with raised eyebrows.Newly approved Liptruzet boasts market-leading efficacy. In studies, it lowered cholesterol by 50%âmaking it the most effective ... [Published Medical Marketing And Media - May 07 2013]

Entities: Zetia, Steve Nissen, Tim Anderson, Lipitor

First reported May 06 2013 - Updated May 06 2013 - 1 reports

AstraZeneca PLC

MSD fined $125k for code breach

MERCK Sharp & Dohme (MSD) has been fined $125,000 and ordered to issue corrective statements relating to its promotion of Vytorin (simvastatin/ezetimibe).Following a complaint by competitor AstraZeneca, the Medicines Australia Code of Conduct Committee ... [Published Medical Observer - May 06 2013]

Entities: Vytorin, Ezetimibe, Simvastatin, AstraZeneca PLC

First reported May 03 2013 - Updated May 04 2013 - 5 reports

Drug to Cut Cholesterol Is Approved by the F.D.A.

The approved on Friday a combination drug developed by Merck that lowers a patients cholesterol but has not been shown to reduce the risk of cardiovascular disease or death, the company said. The drug pairs Mercks Zetia, which lowers low-density lipoprotein ... [Published New York Times - May 04 2013]

Entities: Cholesterol, Zetia, Drugs, Vytorin, Lipitor

First reported May 02 2013 - Updated May 02 2013 - 1 reports

Merck & Co sales slide, $15 billion share buyback unveiled

Merck & Co has suffered a decline in sales and profits in the first quarter, hit by patent expiries on its asthma/allergic rhinitis blockbuster Singulair and disappointing sales for some big-earners, notably the diabetes drug Januvia.Net income came in ... [Published Pharma Times - May 02 2013]

Entities: Merck & Co Inc, Stock Buyback, Ezetimibe, Drugs, sitagliptin

First reported May 01 2013 - Updated May 01 2013 - 1 reports

Merck's Conference Call On A Bad Quarter, Tweet By Tweet

I basically live-tweeted all of Merck’s investor call. Those tweets are below, in chronological order. I’ve edited slightly, only including the tweets I thought gave a clear line of what happened on the call. On the call were Kenneth Frazier, Merck’s ... [Published Forbes.com - May 01 2013]

Entities: Matthew Herper, SITAGLIPTIN, Vytorin, JANUMET

First reported May 01 2013 - Updated May 01 2013 - 1 reports

Merck Net Dips 8%; Approves $15 Billion Stock Buyback

Merck & Co.'s (MRK) first-quarter earnings fell 8.3% as pharmaceutical sales declined amid generic competition for Singulair, which lost U.S. patent protection last year.The pharmaceutical company's board also approved $15 billion in additional share ... [Published Capital.gr - May 01 2013]

Entities: Merck & Co Inc, Stock Buyback, Singulair, Odanacatib, Drugs

First reported Apr 22 2013 - Updated Apr 22 2013 - 2 reports

Merck In-Licenses from Xenon - Analyst Blog

Merck & Co. Inc. (MRK) recently announced the in-licensing of Xenon Pharmaceuticals Inc.’s small molecule compounds for a novel target to treat cardiovascular disease.Merck and Xenon’s agreement dates back to 2009 when the companies entered into a strategic ... [Published Quote.com Japan - Apr 22 2013]

Entities: Merck & Co Inc, Xenon, Zetia, Cardiovascular Disease, Vytorin

Quotes

...track record of getting pharmaceuticals approved by FDA and onto the market speaks for itself," said Robert Freedman, Hurel's Chairman and CEO. "Hurel is privileged to benefit from Jim's extraordinary wisdom and experience, both as a scientist and as a drug development executive. His guidance will be invaluable. We welcome Jim to the Board as a colleague and friend."

Hurel Corporation Appoints Leading Pharmaceutical Executive and Toxicologist Dr. James S. MacDona ... [Published Individual.com - 10 hours ago]

Commenting on the approval of Liptruzet, Tim Anderson, an analyst at Sanford Bernstein, issued a research note saying that "this is certainly not a ‘high science’ product, yet there is something to be said for a drug that can boast the best LDL cholesterol lowering of any single oral agent currently available" , even better than AstraZeneca's Crestor (atorvastatin)

Surprise as Merck & Co cholesterol combo gets FDA OK [Published Pharma Times - May 07 2013]

But the FDA maintains that high LDL levels are a known risk factor for heart disease. "Liptruzet is a combination of two currently marketed drugs that effectively lower elevated levels of LDL cholesterol" an agency spokeswoman told the NYT...

Merck wins FDA nod for new Zetia-Lipitor combo, despite lack of outcomes benefit [Published FiercePharma - May 06 2013]

Peter Jones, who is an associate professorprofessor of medicine at Baylor College of Medicine, said, "Along with a healthy diet, Liptruzet is an effective new lipid-lowering treatment option that may address this unmet need as the complementary actions of its components can provide significant additional LDL lowering beyond atorvastatin therapy alone"

FDA Grants Approval to Merck for Liptruzet Tablets [Published French Tribune - May 06 2013]

More Content

sort by: Date \| Relevance
Hurel Corp. Names MacDonald to Board [Published PE Hub News - 7 hours ago]
Hurel Corporation Appoints Leading Pharmaceutic... [Published Individual.com - 10 hours ago]
ASTRAZENECA - Tremendous Pressure - Messiah to ... [Published TransWorldNews - May 20 2013]
Pick Your Poison: Overweight or High Cholesterol [Published EquityJungle - v0.1 - May 19 2013]
Statin Users May Have a Reason to Rejoice After... [Published EquityJungle - v0.1 - May 19 2013]
Pick Your Poison: Overweight or High Cholesterol [Published Motley Fool - May 18 2013]
US Embassy, USAID Will Attend 14th Conference o... [Published Hondurasweekly - May 17 2013]
Crime rate drops [Published Kelowna Daily Courier - May 17 2013]
Top 10 Cardio Drugs 2012 [Published FiercePharma - May 16 2013]
Concerned about GMOs [Published Kelowna Daily Courier - May 16 2013]
NDP blew their chance [Published Kelowna Daily Courier - May 16 2013]
Genevieve A. Voigt [Published Ozaukee Press - May 16 2013]
Jennifer L. Lemke-Rude [Published Ozaukee Press - May 16 2013]
Jean Lange [Published Ozaukee Press - May 16 2013]
Jerome H. Kroeger [Published Ozaukee Press - May 16 2013]
Tyler Bares [Published Ozaukee Press - May 16 2013]
AMD Recognizes Exemplary Performance of Seven S... [Published AMD Zone - May 15 2013]
FDA Approves Dangerous and Worthless Cholestero... [Published Health Impact News - May 15 2013]
Council tells residents ditches are up to them [Published Kelowna Daily Courier - May 15 2013]
Sony Hardware BS Continues [Published AMD Zone - May 14 2013]
Can Merck’s Pipeline Offset The Pain From Major... [Published Trefis - May 14 2013]
Local candidates make one last push for votes [Published Kelowna Daily Courier - May 14 2013]
Are You Taking This Dangerous Drug? [Published LewRockwell.com - May 13 2013]
The FDA Approval Of Merck's Cholesterol Lowerer... [Published Forbes.com - May 10 2013]
AMD Transforming Into Gaming Company [Published AMD Zone - May 10 2013]
Merck's Liptruzet: A Cause For Shame? [Published BioPortfolio - May 09 2013]
Merck's Liptruzet: A Cause For Shame? [Published Seeking Alpha - May 09 2013]
Merck's Liptruzet: A Cause For Shame? [Published In the Pipeline - May 09 2013]
Earl W. Betzhold [Published Ozaukee Press - May 09 2013]
Merck's Liptruzet Approved in the US - Analyst ... [Published Nasdaq - May 07 2013]

Blogs

sort by: Date \| Relevance
Pick Your Poison: Overweight or High Cholesterol [Published EquityJungle - v0.1 - May 19 2013] Filed under: Investing Overweight and have high cholesterol? You may have to pick one to work on at a time, according to data from the lab of John Thyfault, an associate professor of nutrition and exercise physiology at University of Missouri. Statins ...
Statin Users May Have a Reason to Rejoice After... [Published EquityJungle - v0.1 - May 19 2013] Filed under: Investing Whether or not you've been keeping tabs, the American Society of Clinical Oncology's annual meeting is less than two weeks away. ASCO, as it's more commonly known, is arguably the single-most important event in the biotechnology ...
Merck's Liptruzet: A Cause For Shame? [Published In the Pipeline - May 09 2013] Vytorin's been discussed several times around here. The combination of Zetia (ezetimibe), the cholesterol absorption inhibitor discovered at Schering-Plough, with Merck's simvastatin looked as if it should be a very effective cholesterol-lowering medication, ...
Is Merck Overvalued? [Published Wall St. Cheat Sheet - Apr 15 2013] With shares of Merck & Co. Inc. ( NYSE:MRK ) trading at around $47.11, is MRK an OUTPERFORM, WAIT AND SEE or STAY AWAY? Let’s analyze the stock with the relevant sections of our CHEAT SHEET investing framework : C = Catalyst for the Stock’s Movement ...
FDA, A Tuberculosis Drug And Surrogate Markers [Published Pharmalot - Apr 03 2013] question mark two flickr.jpg question mark two flickr.jpg Late last year, the FDA approved a first-in-class medication to treat multi-drug resistant tuberculosis. The agency did so after an advisory committee unanimously recommended accelerated approval ...

Press Releases

sort by: Date \| Relevance
Fitch: Merck's Settlement of Vytorin Class Acti... [Published Business Wire Professional Services News - Feb 14 2013]
Institutional Investors Recover $688 Million Fr... [Published Marketwire - Breaking News Releases - Feb 14 2013]
The law firms of Bernstein Litowitz Berger & Gr... [Published Financial Services - Jan 25 2013]